Novo picks Clayton, NC for its first U.S. API plant

URLhttp://www.fiercepharmamanufacturing.com/story/nov
SourceFierce Pharma Manufacturing
Date Published08/26/2015
Author NameEric Palmer
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Novo Nordisk
Type of work Manufacturing
If manufacturing, is the company an OEM? Yes
Reshoring category:Transplant
Total number of jobs (added or to be added):700
Year reshoring announced:2015
Year reshoring implemented or to be implemented:2015
Domestically, the work will be done:In-house
Capital investment ($):1200
Country(ies) from which reshored:Denmark
City reshored to:Clayton
State(s) reshored to:NC
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredDrug, insulin ingredients
What non-domestic negative factors made offshoring less attractive?Regulatory compliance
What domestic positive factors made reshoring more attractive?Eco-system synergies, Skilled workforce availability/training
Find Reshoring Articles